Telomir Pharmaceuticals, Inc. TELO
biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging
and age-related diseases rather than treating symptoms alone. Our research strategy targets fundamental cellular processes associated
with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial
dysfunction, and telomere integrity.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $2.4M | $2.2M | $1.6M | $833.2K | — |
| SG&A | $8.1M | $9.6M | $600.2K | $20.9K | — |
| Total operating expenses | $10.5M | $12.2M | $3.9M | $854.1K | — |
| Interest expense | — | $4.3M | $1.6M | — | — |
| Net income | -$10.4M | -$16.5M | -$13.1M | -$854.1K | — |
| EPS, basic | -0.33 | -0.56 | 0.48 | -0.03 | — |
| EPS, diluted | -0.33 | -0.56 | 0.48 | -0.03 | — |
| Shares, diluted (wtd. avg.) | $31.7M | $29.5M | $27.3M | $26.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total current assets | $7.3M | $1.3M | $435.2K | $48.7K | — |
| Total assets | $7.3M | $1.3M | $4.8M | $48.7K | — |
| Accounts payable | $536.8K | $587.5K | $707.2K | $404.2K | — |
| Total current liabilities | $1.4M | $681.0K | $1.3M | $986.0K | — |
| Total liabilities | $1.4M | $681.0K | $1.3M | $986.0K | — |
| Retained earnings | -$41.0M | -$30.6M | -$14.1M | -$992.3K | — |
| Total equity | $5.9M | $643.0K | $3.4M | -$937.3K | -$138.1K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$3.7M | -$5.1M | -$3.9M | -$468.7K | — |
| Stock-based compensation | $5.3M | $6.9M | — | — | — |
| Financing cash flow | $9.7M | $6.3M | $3.9M | $470.1K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-010625.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |